Cutaneous cylindroma is an adnexal tumour with apocrine differentiation. A predisposition to multiple cylindromas is seen in patients with Brooke-Spiegler syndrome, who carry germline mutations in the tumour suppressor gene CYLD. Previous studies of inherited cylindromas have highlighted the frequent presence of bi-allelic truncating CYLD mutations as a recurrent driver mutation. We have previously shown that sporadic cylindromas express either MYB-NFIB fusion transcripts or show evidence of MYB activation in the absence of such fusions. Here, we investigated inherited cylindromas from several families with germline CYLD mutations for the presence of MYB activation. Strikingly, none of the inherited CYLD-defective (n = 23) tumours expressed MYB-NFIB fusion transcripts. However, MYB expression was increased in the majority of tumours (69%) and global gene expression analysis revealed that well-established MYB target genes were up-regulated in CYLD-defective tumours. Moreover, knock-down of MYB expression caused a significant reduction in cylindroma cell proliferation, suggesting that MYB is also a key player and oncogenic driver in inherited cylindromas. Taken together, our findings suggest molecular heterogeneity in the pathogenesis of sporadic and inherited cutaneous cylindromas, with convergence on MYB activation. © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Breakthrough Breast Cancer Research Centre Institute of Cancer Research London UK

Institute of Genetic Medicine Newcastle University Newcastle upon Tyne UK

Sahlgrenska Cancer Centre Department of Pathology University of Gothenburg Sweden

Sikl's Department of Pathology Charles University Prague Medical Faculty in Pilsen Czech Republic

UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA USA

J Pathol. 2016 Aug;239(4):391-3. doi: 10.1002/path.4746. PubMed

See more in PubMed

Persson M, Andren Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 2009; 106: 18740–18744. PubMed PMC

Persson M, Andren Y, Moskaluk CA, et al. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer 2012; 51: 805–817. PubMed

Stenman G, Persson F, Andersson MK. Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol 2014; 50: 683–690. PubMed

Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer 2008; 8: 523–534. PubMed

Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumour‐suppressor gene. Nat Genet 2000; 25: 160–165. PubMed

Fehr A, Kovacs A, Loning T, et al. The MYB–NFIB gene fusion – a novel genetic link between adenoid cystic carcinoma and dermal cylindroma. J Pathol 2011; 224: 322–327. PubMed

Rajan N, Elliott R, Clewes O, et al. Dysregulated TRK signalling is a therapeutic target in CYLD‐defective tumours. Oncogene 2011; 30: 4243–4260. PubMed PMC

Jungehulsing M, Wagner M, Damm M. Turban tumour with involvement of the parotid gland. J Laryngol Otol 1999; 113: 779–783. PubMed

Grossmann P, Vanecek T, Steiner P, et al. Novel and recurrent germline and somatic mutations in a cohort of 67 patients from 48 families with Brooke–Spiegler syndrome, including the phenotypic variant of multiple familial trichoepitheliomas and correlation with the histopathologic findings in 379 biopsy specimens. Am J Dermatopathol 2013; 35: 34–44. PubMed

Kacerovska D, Szep Z, Kollarikova L, et al. A novel germline mutation in the CYLD gene in a Slovak patient with Brooke–Spiegler syndrome. Cesk Patol 2013; 49: 89–92. PubMed

Kazakov DV, Zelger B, Rutten A, et al. Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke–Spiegler syndrome. Am J Surg Pathol 2009; 33: 705–719. PubMed

Vanecek T, Halbhuber Z, Kacerovska D, et al. Large germline deletions of the CYLD gene in patients with Brooke–Spiegler syndrome and multiple familial trichoepithelioma. Am J Dermatopathol 2014; 36: 868–874. PubMed

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real‐time quantitative PCR and the 2–ΔΔCt method. Methods 2001; 25: 402–408. PubMed

von Holstein SL, Fehr A, Persson M, et al. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics. Ophthalmology 2013; 120: 2130–2138. PubMed

Massoumi R. Ubiquitin chain cleavage: CYLD at work. Trends Biochem Sci 2010; 35: 392–399. PubMed

Pahl HL. Activators and target genes of Rel/NF‐κB transcription factors. Oncogene 1999; 18: 6853–6866. PubMed

Rajan N, Langtry JA, Ashworth A, et al. Tumor mapping in two large multigenerational families with CYLD mutations: implications for disease management and tumor induction. Arch Dermatol 2009; 145: 1277–1284. PubMed PMC

Biggs PJ, Chapman P, Lakhani SR, et al. The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas. Oncogene 1996; 12: 1375–1377. PubMed

Massoumi R, Chmielarska K, Hennecke K, et al. Cyld inhibits tumor cell proliferation by blocking Bcl‐3‐dependent NF‐κB signaling. Cell 2006; 125: 665–677. PubMed

Ivanov SV, Panaccione A, Brown B, et al. TrkC signaling is activated in adenoid cystic carcinoma and requires NT‐3 to stimulate invasive behavior. Oncogene 2013; 32: 3698–3710. PubMed

Petersson F, Kutzner H, Spagnolo DV, et al. Adenoid cystic carcinoma‐like pattern in spiradenoma and spiradenocylindroma: a rare feature in sporadic neoplasms and those associated with Brooke–Spiegler syndrome. Am J Dermatopathol 2009; 31: 642–648. PubMed

Stephens PJ, Davies HR, Mitani Y, et al. Whole‐exome sequencing of adenoid cystic carcinoma. J Clin Invest 2013; 123: 2965–2968. PubMed PMC